Back

Discussant review - CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease

17 May 2025 (12:11 - 12:14)
Organised by: Logo
Congress Presentation Part of: Hottest trials and trial updates (1) Clinical HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Rudolf De Boer

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

20 More presentations in this session

Presentation thumbnail
FINEARTS­HF: Blinded drug withdrawal
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
Discussant review - FINEARTS-HF
Doctor M. Costanzo (Naperville, US)
Slides Video
Presentation thumbnail
Panel discussion - FINEARTS-HF
Video
Presentation thumbnail
FAIR-HF2 DZHK05: Efficacy of ferric carboxymaltose in heart failure and iron deficiency stratified by transferrin saturation
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
Discussant review - FAIR-HF2 DZHK05
Doctor V. Chopra (New Delhi, IN)
Slides Video

Access the full session

Session thumbnail
Hottest trials and trial updates (1)
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 12:11 CET
You may be interested in
thumbnail
Congress Presentation
CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease
thumbnail
Congress Presentation
CMR outcomes following one-time in vivo CRISPR editing with nexiguran ziclumeran in patients with ATTR-CM: phase 1 results
thumbnail
Congress Presentation
Panel discussion - CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources